0001802806-24-000016.txt : 20240223 0001802806-24-000016.hdr.sgml : 20240223 20240223171307 ACCESSION NUMBER: 0001802806-24-000016 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240223 DATE AS OF CHANGE: 20240223 EFFECTIVENESS DATE: 20240223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CERO THERAPEUTICS HOLDINGS, INC. CENTRAL INDEX KEY: 0001870404 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871088814 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-506000 FILM NUMBER: 24672546 BUSINESS ADDRESS: STREET 1: 201 HASKINS WAY STREET 2: SUITE 230 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-407-2376 MAIL ADDRESS: STREET 1: 201 HASKINS WAY STREET 2: SUITE 230 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: PHOENIX BIOTECH ACQUISITION CORP. DATE OF NAME CHANGE: 20210630 D 1 primary_doc.xml X0708 D LIVE 0001870404 CERO THERAPEUTICS HOLDINGS, INC. 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 650-407-2376 DELAWARE PHOENIX BIOTECH ACQUISITION CORP. Corporation true 2021 Brian Atwood c/o 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Michael Byrnes c/o 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Lindsey Rolfe c/o 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Robyn Rapaport c/o 201 Haskins Way, Suite 230 South San Francisco CA CALIFORNIA 94080 Director Pharmaceuticals No Revenues 06b false 2024-02-14 false true true true true In connection with PBAX and CERo's business combination, we issued and sold shares of Series A Preferred Stock, warrants to purchase Common Stock and warrants to purchase Series A Preferred Stock for aggregate cash proceeds of approx. $10.2 million. 0 J.V.B. Financial Group, LLC 149758 None None 1825 NW Corporate Blvd Ste 100 Boca Raton FL FLORIDA 33431 All States false 10193654 10193654 0 false 46 1162000 0 We entered into fee modification agreements with the placement agent to which the placement agent agreed to receive an aggregate of 1,200,000 shares of Common Stock, valued at $1,162,000, in lieu of accrued fees for prior services. 227762 A portion of the Series A Preferred Stock was issued as consideration for the cancellation of outstanding indebtedness or securities of PBAX or CERo, including a promissory note and convertible bridge notes. false CERO THERAPEUTICS HOLDINGS, INC. /s/ Charles Carter Charles Carter Chief Financial Officer 2024-02-23